About Pulmatrix Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.pulmatrix.com/
Frequently Asked Questions
What is the 52-week range for PULM?
The 52-week high is $5.498 and the 52-week low is $1.16.
What is the P/E ratio for PULM?
The P/E ratio data is currently unavailable.
What is the dividend yield for PULM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -96.97%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -122.46%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.14.
Analyst Recommendation Trends
Wall Street analyst consensus for PULM over the last few months:
Latest PULM News
Eos SENOLYTIX to Highlight Next-Generation Mitochondria-Targeted Therapeutics at 17th World Congress on Targeting Mitochondria
Founder and CEO Kevin Slawin, M.D., to deliver industry keynote on advancing mitochondrial-targeted geropeptide medicineEos advancing lead candidate MitoXcel™ geropeptide PTC-2105 toward first-in-human studies for sarcopenia and sarcopenic obesityEos anticipates closing of Pulmatrix, Inc. merger in Q4 subject to customary closing conditions HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Eos SENOLYTIX, Inc. (“Eos” or the “Company”), a biotechnology company developing first-in-class mitochondrial-tar
Eos SENOLYTIX Advances Lead Candidate MitoXcel Geropeptide PTC-2105 Toward First-In-Human Studies For Sarcopenia And Sarcopenic Obesity
Advancing PTC-2105 Toward the ClinicEos is in the preclinical stage of development of PTC-2105 and is conducting IND-enabling studies to support the initiation of first-in-human clinical trials, which will be led by
Eos SENOLYTIX CEO To Deliver Industry Keynote On Advancing Mitochondrial-Targeted Geropeptide Medicine; Co. Expects To Close Pulmatrix Merger In Q4
Eos SENOLYTIX, Inc. ("Eos" or the "Company"), a biotechnology company developing first-in-class mitochondrial-targeted gerotherapeutics designed to improve body composition, physical function, and
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-02-03 | Higgins Michael J | +8,800 | - | - |